Home  |  Choose language  |  Contact  Contact
Search  |  Sitemap  |  Links
Company News Human Medicine Industrial Group Veterinary Medicine Jobs & Careers
09.10.2007

Joining forces in the battle against cancer, myocardial infarction or Alzheimer’s disease

Together with the German Federal Ministry of Research and Education, five German pharmaceutical and medical device companies are starting the “Technology Initiative Molecular Imaging“

Copyright KARL STORZ GmbH & Co. KG
from left: Dr. Hertkorn (Boehringer Ingelheim), Karl-Christian Storz (KARL STORZ GmbH & Co. KG), Bundesforschungsministerin Dr. Annette Schavan, Dr. Kaschke (Carl Zeiss), Prof. Dr. Busch (Bayer-Schering) and Prof. Dr. Reinhardt (Siemens)
Early detection of cancer, Alzheimer’s or cardiovascular diseases, effective therapies and greater efficiency throughout the healthcare system – these are the key goals of the “Technology Initiative - Molecular Imaging” which was set forth today by five leading pharmaceutical and medical device companies as well as the German Federal Ministry of Research and Education (BMBF).

Copyright KARL STORZ GmbH & Co. KG
Karl-Christian Storz

Bayer Schering Pharma, Boehringer Ingelheim Pharma, Siemens Medical Solutions, Karl Storz and Carl Zeiss will spend a total of 750 million Euros during the next ten years for the development of new methods in molecular imaging. In the next six years, BMBF will also promote cooperative R&D projects in the amount of 150 million Euros.


Press Release

Joint Press Release by Bayer Schering Pharma, Boehringer Ingelheim Pharma, Siemens Medical Solutions, Karl Storz und Carl Zeiss Download

Further links

© Copyright KARL STORZ GmbH & Co. KG, Tuttlingen